Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles
Diabetes Care · 2024
DOI: 10.2337/dc24-0198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2024. Verfasst von Mohamed Ghalwash und 10 weiteren Autor:innen. Beteiligte Einrichtung: T.J. Watson Research Center, IBM, Yorktown Heights, NY. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoantibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Breakthrough T1D, JDRF.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To characterize distinct islet autoantibody profiles preceding stage 3 type 1 diabetes RESEARCH DESIGN AND METHODS The T1DI (Type 1 Diabetes Intelligence) study combined data from 1,845 genetically susceptible prospectively observed children who were positive for at least one islet autoantibody: insulin autoantibody (IAA), GAD antibody (GADA), or islet antigen 2 antibody (IA-2A). Using a novel similarity algorithm that considers an individual’s temporal autoantibody profile, age at autoantibody appearance, and variation in the positivity of autoantibody types, we performed an unsupervised hierarchical clustering analysis. Progression rates to diabetes were analyzed via survival analysis. RESULTS We identified five main clusters of individuals with distinct autoantibody profiles characterized by seroconversion age and sequence of appearance of the three autoantibodies. The highest 5-year risk from first positive autoantibody to type 1 diabetes (69.9%; 95% CI 60.0–79.2) was observed in children who first developed IAA in early life (median age 1.6 years) followed by GADA (1.9 years) and then IA-2A (2.1 years). Their 10-year risk was 89.9% (95% CI 81.9–95.4). A high 5-year risk was also found in children with persistent IAA and GADA (39.1%) and children with persistent GADA and IA-2A (30.9%). A lower 5-year risk (10.5%) was observed in children with a late appearance of persistent GADA (6.1 years). The lowest 5-year diabetes risk (1.6%) was associated with positivity for a single, often reverting, autoantibody. CONCLUSIONS The novel clustering algorithm identified children with distinct islet autoantibody profiles and progression rates to diabetes. These results are useful for prediction, selection of individuals for prevention trials, and studies investigating various pathways to type 1 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- T.J. Watson Research Center, IBM, Yorktown Heights, NY.
- Faculty of Science, Ain Shams University, Cairo, Egypt.
- T.J. Watson Research Center, IBM, Cambridge, MA.
- JDRF, New York, NY.
- Department of Clinical Sciences, Lund University/Clinical Research Centre, Skåne University Hospital, Malmö, Sweden.
- Pacific Northwest Research Institute, Seattle, WA.
ORCID-Profile: Vibha Anand, Kenney Ng, Anette-G Ziegler, Riitta Veijola
Förderung
- NIDDK NIH HHS
- Breakthrough T1D
- JDRF
Zitieren
APA
Ghalwash, M., Anand, V., Ng, K., Dunne, J. L., Lou, O., Lundgren, M., Hagopian, W. A., Rewers, M., Ziegler, A. G., Veijola, R., & T1DI Study Group (2024). Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles. Diabetes Care. https://doi.org/10.2337/dc24-0198
Vancouver
Ghalwash M, Anand V, Ng K, Dunne JL, Lou O, Lundgren M, et al. Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles. Diabetes Care. 2024. doi:10.2337/dc24-0198
BibTeX
@article{Ghalwash2024,
author = {Ghalwash, Mohamed and Anand, Vibha and Ng, Kenney and Dunne, Jessica L and Lou, Olivia and Lundgren, Markus and Hagopian, William A and Rewers, Marian and Ziegler, Anette-G and Veijola, Riitta and T1DI Study Group, T1DI Study Group},
title = {Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles},
journal = {Diabetes Care},
year = {2024},
doi = {10.2337/dc24-0198}
}
EUVIMED